SCHEMBL10277072

SCHEMBL10277072

O=C(NCl)Oc1ccc(F)cc1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FAAH O00519 4/20 0.49
ALDH1A1 P00352 4/20 0.49
CYP1A2 P05177 3/20 0.49
KDM4E B2RXH2 1/20 0.49
HPGD P15428 1/20 0.49
KMT2A Q03164 2/20 0.42
ATM Q13315 1/20 0.42
S1PR2 O95136 1/20 0.41
CYP3A4 P08684 2/20 0.40
CYP2C9 P11712 2/20 0.40
TSHR P16473 2/20 0.40
CYP2C19 P33261 2/20 0.40
CYP2D6 P10635 1/20 0.40
MAPT P10636 1/20 0.40
LIPE Q05469 1/20 0.40
CES2 O00748 1/20 0.39
CES1 P23141 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14783522 0.84 FAAH (0.50) FAAHALDH1A1CYP1A2KDM4EHPGD
SCHEMBL6924040 0.81 ALDH1A1 (0.51) FAAHALDH1A1CYP1A2KDM4EHPGD
SCHEMBL11175838 0.81 LMNA (0.57) ALDH1A1CYP1A2KMT2ACYP3A4CYP2C9
SCHEMBL9267073 0.80 ALDH1A1 (0.52) ALDH1A1CYP1A2KDM4EHPGDKMT2A
SCHEMBL28962581 0.78 ALDH1A1 (0.53) FAAHALDH1A1CYP1A2KDM4EHPGD
SCHEMBL696908 0.77 KMT2A (0.44) FAAHALDH1A1CYP1A2KDM4EHPGD
SCHEMBL57245 0.77 KMT2A (0.50) FAAHALDH1A1CYP1A2KDM4EHPGD
SCHEMBL11339293 0.76 FAAH (0.52) FAAHALDH1A1CYP1A2KDM4EHPGD
SCHEMBL16918662 0.76 FAAH (0.60) FAAHALDH1A1CYP1A2KDM4EHPGD
SCHEMBL22289601 0.76 ALDH1A1 (0.48) FAAHALDH1A1CYP1A2KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2661432-B1 PYRROLIDINE DERIVATIVES AS NK3 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2014-11-19 EP disclosed
US-8618303-B2 Pyrrolidine derivatives HOFFMANN-LA ROCHE INC. (US) 2013-12-31 US disclosed
EP-2661432-A1 PYRROLIDINE DERIVATIVES AS NK3 ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2013-11-13 EP disclosed
US-20120178761-A1 PYRROLIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2012-07-12 US disclosed
WO-2012093109-A1 PYRROLIDINE DERIVATIVES AS NK3 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2012-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178761-A1 PYRROLIDINE DERIVATIVES SLC6A3, NPSR1, TACR1 FAAH 1738/4885ALDH1A1 377/4885CYP1A2 1491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.